Synthorx (Synthorx) Earnings per Share (Diluted) : $-4.06 (TTM As of Sep. 2019)

View and export this data going back to 2018. Start your Free Trial

What is Synthorx Earnings per Share (Diluted)?

Synthorx's Earnings per Share (Diluted) for the three months ended in Sep. 2019 was $-0.38. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-4.06.

Synthorx's EPS (Basic) for the three months ended in Sep. 2019 was $-0.38. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2019 was $-4.06.

Synthorx's EPS without NRI for the three months ended in Sep. 2019 was $-0.38. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2019 was $-4.06.

Synthorx Earnings per Share (Diluted) Historical Data

The historical data trend for Synthorx's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synthorx Earnings per Share (Diluted) Chart

Synthorx Annual Data

Trend

Dec16

Dec17

Dec18

Earnings per Share (Diluted)

-0.36

-0.68

-18.11

Synthorx Quarterly Data
	Dec16	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Earnings per Share (Diluted)	Get a 7-Day Free Trial				-0.81	-2.94	-0.35	-0.39	-0.38

Competitive Comparison of Synthorx's Earnings per Share (Diluted)

For the Biotechnology subindustry, Synthorx's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synthorx's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synthorx's PE Ratio distribution charts can be found below:

* The bar in red indicates where Synthorx's PE Ratio falls into.

Synthorx Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Synthorx's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2018 is calculated as

Diluted Earnings Per Share (A: Dec. 2018 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-56.609	-	0)	/	3.125
	=	-18.11

Synthorx's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2019 is calculated as

Diluted Earnings Per Share (Q: Sep. 2019 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-12.216	-	0)	/	31.788
	=	-0.38

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.06

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Synthorx (NAS:THOR) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Synthorx Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Synthorx's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Synthorx (Synthorx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synthorx Inc (NAS:THOR) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

11099 North Torrey Pines Road, Suite 290, La Jolla, CA, USA, 92037

Website

http://www.synthorx.com

Executives

Powell Andrew Kenneth William	director	C/O COLLAGENEX PHARMACEUTICALS, INC., 41 UNIVERSITY DRIVE, NEWTOWN PA 18940
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jay Lichter	director	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Laura Shawver	director, officer: President and CEO	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Avalon Ventures X, L.p.	10 percent owner	1134 KLINE STREET, LA JOLLA CA 92037
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022